In a report released on March 14, Dylan Van Haaften from Stifel Nicolaus maintained a Buy rating on DiaSorin S.p.A. (0GZX – Research Report), with a price target of €115.00.
Dylan Van Haaften’s rating is based on several key factors that highlight DiaSorin S.p.A.’s potential for growth. Despite a slight miss in the fourth quarter results compared to consensus expectations, the company met its full-year 2024 guidance, which provides a stable foundation for future performance. The guidance for 2025 aligns with market expectations and indicates a conservative yet promising start to the year.
Van Haaften notes that while the Molecular Diagnostics segment underperformed in the fourth quarter, the management’s positive commentary on the LIAISON PLEX uptake and purchasing patterns provides reassurance. The expected revenue from PLEX is considered achievable, and the company’s growth algorithm for 2025 appears robust, with significant growth anticipated in Immunodiagnostics and Molecular Diagnostics. Additionally, the EBITDA margin guidance is in line with expectations, and the potential for PLEX to drive positive surprises further supports the Buy rating. Overall, these factors contribute to a confident outlook for DiaSorin’s stock performance.